This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Coherus BioSciences, Inc.
Drug Names(s): AMG 131, T131, T0903131, INT131
Description: INT131 is PPAR gamma selective modulator and partial agonist. PPAR gamma nuclear receptors regulate the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPAR gamma-responsive genes also participate in the regulation of fatty acid metabolism.
Animal studies of INT131 demonstrated greater potency and equal efficacy compared to Avandia, a marketed diabetes agent targeting PPAR gamma. INT131 caused less weight gain than Avandia in animal models.
Deal Structure: Amgen acquired T131 on August 13, 2004 through its acquisition of Tularik.
In January 2007, InteKrin Therapeutics entered into a license agreement with Amgen under which InteKrin has obtained worldwide development and commercialization rights to INT131.
Coherus and Intekrin
In February 2014, Coherus acquired InteKrin Therapeutics for total consideration of $5.0 million.
Partners: Amgen, Inc.
Pink Sheet Weekly Trademark Review Jan. 17, 2017
Additional information available to subscribers only: